• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Allogene Therapeutics, Inc. - Common Stock (NQ:ALLO)

2.090 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Allogene Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Allogene Therapeutics Announces Planned CEO Succession
May 28, 2026
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
May 26, 2026
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Q1 Earnings Call Highlights ↗
May 13, 2026
Allogene Therapeutics (NASDAQ:ALLO) said its first quarter of 2026 was marked by early clinical progress for its lead allogeneic CAR-T programs and a strengthened cash position following an April... 
Via MarketBeat
Topics Earnings
News headline image
Allogene (ALLO) Q1 2026 Earnings Transcript ↗
May 13, 2026
Allogene (ALLO) Q1 2026 Earnings Transcript 
Via The Motley Fool
Allogene Therapeutics Inc (NASDAQ:ALLO) Reports Narrower-Than-Expected Q4 Loss, Highlights Key 2026 Clinical Catalysts ↗
March 12, 2026
Via Chartmill
News headline image
Allogene Therapeutics Q1 2026 Earnings Call Transcript ↗
May 13, 2026
 
Via Benzinga
Topics Earnings
News headline image
Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update
May 13, 2026
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
May 06, 2026
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia
April 21, 2026
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026
April 20, 2026
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock
April 16, 2026
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Thursday's session: gap up and gap down stocks ↗
April 16, 2026
Via Chartmill
News headline image
Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases
April 15, 2026
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Announces Pricing of Public Offering of Common Stock
April 14, 2026
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
JPMorgan, Allogene Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
April 14, 2026
US stock futures mixed, Nasdaq 100 up over 50 points. JPMorgan shares down 3.1% after beating earnings but missing sales estimates. Other stocks also down in pre-market trading. 
Via Benzinga
News headline image
Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock
April 13, 2026
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
These stocks are making the most noise in today's session. ↗
April 13, 2026
Stay updated with the latest market activity on Monday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight. 
Via Chartmill
News headline image
ENDRA Life Sciences (NASDAQ: NDRA) Targets Billions With TAEUS® Liver Imaging Technology
April 13, 2026
Via AB Newswire
News headline image
Allogene Therapeutics Stock Hits 52-Week High - Here's Why ↗
April 13, 2026
Allogene's ALPHA3 trial shows strong MRD clearance and ctDNA reduction, signaling potential to delay relapse in lymphoma patients. 
Via Benzinga
News headline image
These stocks are gapping in today's session ↗
April 13, 2026
Let's have a look at what is happening on the US markets on Monday. Below you can find the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Leggett & Platt, Allogene Therapeutics, Revolution Medicines And Other Big Stocks Moving Higher On Monday ↗
April 13, 2026
U.S. stocks were mixed on Monday, with the Dow Jones falling over 200 points. Leggett & Platt rose on news of being acquired by Somnigroup. 
Via Benzinga
Topics Stocks
News headline image
Which stocks are moving before the opening bell on Monday? ↗
April 13, 2026
Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL
April 13, 2026
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Get insights into the top gainers and losers of Friday's after-hours session. ↗
April 10, 2026
The regular session of the US market on Friday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
News headline image
Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026
April 10, 2026
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene (ALLO) Q4 2025 Earnings Call Transcript ↗
March 12, 2026
Allogene (ALLO) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
March 12, 2026
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update
March 02, 2026
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
February 05, 2026
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Stock Market Today, Jan. 21: ImmunityBio Rises Again As Short-Sellers Face Losses ↗
January 21, 2026
On Jan. 21, 2026, the market weighed ImmunityBio’s skyrocketing share price, surging volume, and the company's heavily-shorted stock. 
Via The Motley Fool
Topics Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap